The American Journal of Managed Care

Sequencing, Real-World Evidence, and Unmet Needs: Key Immunotherapy Insights From ASH 2025 in Multiple Myeloma

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...
The American Journal of Managed Care

Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...
Healio

Rheumatologists view CAR T-cell therapy as ‘revolutionary,’ but cost, safety temper enthusiasm

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
EurekAlert!

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

(ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as ...
ascopubs.org

Real-life use of G-CSF in patients with small cell lung cancer (SCLC): Secondary data analysis from the French national cohorts KBP-ESCAP-2020-CPHG.

Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board. Definition of Febrile ...
ascopubs.org

Real world adverse events of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy.

Differences in age of diagnosis and survival period for individuals of Asian Indian/Pakistani origin and American Indian/Alaskan natives with multiple myeloma using Surveillance, Epidemiology, and End ...